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Systemic lupus erythematosus (SLE) (lupus) is a chronic 
autoimmune disease characterized by the production of 
autoantibody against several self-antigens such as 
double-stranded DNA (dsDNA), phospholipids, and 
apolipoproteins. Individuals suﬀ  ering from lupus usually 
develop a myriad of comorbidities, including hemolytic 
anemia, neuropathies, glomerulonephritis, and cardio-
vas  cular disease (CVD). In the mid-1970s, Urowitz and 
colleagues [1] demonstrated a bimodal mortality in 
which individuals who died soon after diagnosis usually 
succumbed to either kidney disease or infection (due to 
extensive immunosuppressive therapy) whereas those 
who survived longer past diagnosis most likely developed 
CVD. In 1997, a seminal paper by Manzi and colleagues 
[2] reported for the ﬁ  rst time that the risk for developing 
CVD and myocardial infarction is signiﬁ  cantly increased 
in premenopausal women. Since that time, numerous 
studies have described the existence of premature 
subclinical and accelerated atherosclerosis in patients 
with lupus (reviewed in [3]). To make matters worse, 
many patients with lupus do not exhibit the traditional 
risk factors for atherosclerosis, namely increased low-
density lipoprotein (LDL) cholesterol and decreased 
high-density lipoprotein (HDL) cholesterol. Instead, 
most patients develop dyslipidemia characterized by 
increased triglyceride and slight decreases in HDL but no 
signiﬁ  cant increase in LDL cholesterol. Th  erefore, it is 
possible that the traditional LDL-lowering therapies that 
have been so successful in treating CVD and athero-
sclerosis in the general population may not have the same 
eﬀ  ect in patients with lupus.
By now, it is commonly accepted that HDL and apo-
lipoprotein-AI (Apo-AI) are cardio-protective in both 
humans and mouse models of atherosclerosis. However, 
it was recently demonstrated that individuals suﬀ  ering 
from active SLE can develop a dysfunctional HDL deﬁ  ned 
as inﬂ  ammatory HDL [4]. Th  is modiﬁ  ed lipoprotein is 
characterized by reduced concentrations of Apo-AI and 
paraoxonase, molecules important for mobilizing 
cholesterol from cells and protecting LDL from oxidative 
modiﬁ  cations, respectively. Th   erefore, patients with SLE 
have a particular disadvantage in both levels and pheno-
type of protective HDL.
Owing to the cardio-protective nature of Apo-AI, 
research has been focused on developing eﬀ  ective Apo-
AI-based therapies for CVD. One approach shown to be 
eﬀ  ective in reducing atherosclerosis and systemic inﬂ  am-
mation in mice is the use of synthetic peptides that mimic 
Apo-AI in both structure and function [5,6]. Th  ese 
mimetics, termed D-4F and L-4F, can increase the ability 
of HDL cholesterol to protect LDL from oxidation, 
increase HDL levels, and increase cholesterol eﬄ   ux from 
cells [7]. Th  erefore, it is a logical extension that these 
peptides should be tested for their abilities to increase 
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as a possible mechanism of protection from accelerated 
atherosclerosis.
Undoubtedly, one of the most popular, and successful, 
therapies for the management of CVD and lipids in the 
general population has been the use of statins. Given that 
statins have had positive clinical eﬀ  ects in patients with 
rheumatoid arthritis, it is logical to expect that 
individuals with SLE would likewise beneﬁ   t from this 
therapy [8]. Unfortunately, the clinical studies testing 
statin use in patients with SLE have not been very 
promising [9]. In a study published recently in Arthritis 
Research & Th  erapy, Woo and colleagues [10] investi-
gated whether statin therapy might have positive eﬀ  ects 
in a mouse model of lupus-mediated accelerated athero-
sclerosis and osteoporosis.
In that study, Woo and colleagues [10] tested the 
hypothesis that treatment of apoE-deﬁ  cient  (apoE−/−) 
mice lacking Fas (hereafter referred to as apoE−/−Fas−/−), 
with a high-dose statin, pravastatin (5 mg/kg), either 
alone or in combination with the Apo-AI mimetic, L-4F, 
could decrease the progression of atherosclerosis and 
have positive eﬀ   ects on osteoporosis. Th  e  authors 
observed, in agreement with the anti-inﬂ  ammatory 
properties of Apo-AI, a decrease in autoantibody titers to 
dsDNA and oxidized phospholipid as well as a reduction 
in glomerulus tuft size, proteinuria, and lymphocyte 
inﬁ  ltration in mice treated with L-4F or L-4F plus prava-
statin compared with the vehicle-treated group. Sur-
prisingly, the anti-inﬂ  ammatory eﬀ  ect of this treatment 
was accompanied by an increase in aortic root athero-
sclerotic lesion area in apoE−/−Fas−/− mice that received 
L-4F, pravastatin, or combination therapy, despite reduced 
interleukin-10 and chemokine levels and decreased 
VCAM-1 (vascular cell adhesion molecule-1) expression 
on endothelial cells. Th  is eﬀ   ect was independent of 
circulating lipoprotein levels. Interestingly, combination 
therapy, but not L-4F or pravastatin therapy alone, 
resulted in decreased macrophage inﬁ  ltration and plaque 
remodeling, suggestive of a more stable plaque. 
Furthermore, L-4F therapy resulted in the improvement 
of bone density in these mice. Because plaque stability 
and not just plaque size is important for protection 
against the deadly manifestations of atherosclerosis (a 
view that is commonly accepted), combination therapies 
using Apo-AI mimetics and statin might oﬀ  er a good 
additional therapy to treat autoimmunity and associated 
CVD and osteoporosis in patients with SLE.
Collectively, the ﬁ  ndings of Woo and colleagues [10] 
represent a glimmer of hope for a group of patients who 
have not had a major breakthrough in treatment in the 
past 30 years. Patients with SLE are subject to a large 
number of comorbidities; two of the more severe 
comorbidities are accelerated atherosclerosis and 
increased risk of myocardial infarction. Although L-4F 
and other Apo-AI mimetics may have positive eﬀ  ects on 
SLE symptoms and plaque stability, the increase in total 
lesion area obviously represents a signiﬁ  cant hurdle for 
the practical use of these molecules in the clinic.
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